ArticleSurgical neurology international2026
Craniofacial surgery for removing tumors in advanced stages that invade the anterior skull base.
Article in Surgical neurology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Craniofacial surgery provides optimal exposure of the sinonasal cavity, epidural space, and intracranial anterior fossa compartments, facilitating oncologically Methods: Between 2013 and 2025, 228 consecutive patients underwent craniofacial surgery at the Hospital de Especialidades del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico. Data on clinical presentation, tumor histology, type of approach, and surgical outcomes were retrospectively investigated in institutional databases. Results: There were 128 males (56.1%), and the mean age was 50.8 years. The most frequent symptoms were nasal obstruction (60%), epistaxis/rhinorrhea (54.3%), cephalea/facial pain (41.2%), and olfactory disturbances (27.1%). The most frequent neoplasms were epidermoid carcinoma (19.2%), esthesioneuroblastoma (13.5%), and inverted papilloma (8.3%). The most frequently performed cranial approach was the transbasal subfrontal approach (67.9%). A total of 32.4% of patients experience progression/recurrence of their disease. Infection was the most frequent complication (4.8%). Neoadjuvant therapy was administered at 12.7%. Adjuvant therapy, such as radiotherapy (RT), was administered at 36.8%, chemotherapy (CMT) at 5.2%, and RT + CMT at 24.5%. The mean follow-up time was 51.2 months. The immediate postoperative survival rate was 100%; at 6 months, it was 94.7%; at 1 year, it was 84.2%; and at 3 years, it was 51.7%. There was no perioperative mortality. Conclusion: The combination of a subfrontal-transbasal plus midfacial degloving approach is preferable for neoplasms located in the anterior skull base because they are generally very large at the time of diagnosis, mainly for the management of malignancies in advanced stages. Histology, localization, extension, relation with neurovascular structures, extra or intracranial, and extra or intradural invasion are factors to consider in the selection of the surgical approach. Multidisciplinary management is the key to getting successful results in the treatment of tumors in these areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.